WHO ICTRP trial
Radiotherapy combined with immunotherapy in metastatic non-small cell lung…
ISRCTN49817477 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN49817477 |
|---|---|
| Public title | Radiotherapy combined with immunotherapy in metastatic non-small cell lung cancer patients |
| Scientific title | Multicentre, randomised, phase II study examining the activity of L19-IL2 immunotherapy and Stereotactic ABlative Radiotherapy in metastatic non-small cell lung cancer: ImmunoSABR |
| Primary sponsor | Maastricht University |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Belgium;France;Germany;Italy;Netherlands;United Kingdom;England |
| Conditions | Advanced non-small cell lung cancer, stage IV Cancer Malignant neoplasm the lung, non-small cell lung cancer |
| Interventions | The patients included in the trial will be stratified for the metastatic load (oligo; max 5 or diffuse; 6-10 metastases). After randomisation, patients will be assigned either to the experimental arm or the standard of care (SOC) arm… |
| Registration date | Jul 6, 2020 |
| Target size | 126 |
| Secondary IDs | 2018-002583-11;NCT03705403;IRAS 261785 , 18-068 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: